5/9
12:11 pm
cvkd
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
5/9
09:17 am
cvkd
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update [Yahoo! Finance]
Medium
Report
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update [Yahoo! Finance]
5/9
09:00 am
cvkd
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Medium
Report
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
4/20
10:12 am
cvkd
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]
Low
Report
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock [Yahoo! Finance]
4/11
04:40 pm
cvkd
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 [Yahoo! Finance]
Medium
Report
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 [Yahoo! Finance]
4/11
04:30 pm
cvkd
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
Low
Report
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
4/9
09:12 am
cvkd
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts [Yahoo! Finance]
High
Report
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts [Yahoo! Finance]
4/9
09:00 am
cvkd
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
High
Report
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
4/8
06:40 am
cvkd
Zura Bio names new executive chief [Seeking Alpha]
Medium
Report
Zura Bio names new executive chief [Seeking Alpha]
4/8
06:07 am
cvkd
Zura Bio Announces Robert Lisicki as CEO and Director [Yahoo! Finance]
Medium
Report
Zura Bio Announces Robert Lisicki as CEO and Director [Yahoo! Finance]
3/18
03:09 pm
cvkd
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/11
09:12 am
cvkd
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update [Yahoo! Finance]
Low
Report
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update [Yahoo! Finance]
3/11
09:00 am
cvkd
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
Low
Report
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
2/26
09:11 am
cvkd
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference [Yahoo! Finance]
Low
Report
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference [Yahoo! Finance]
2/26
09:00 am
cvkd
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
Low
Report
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference